Friday, December 1, 2023
HomeLatest Pharma-NewsRoche presents pivotal First Phase III cancer immunotherapy Tecentriq in combination with...

Roche presents pivotal First Phase III cancer immunotherapy Tecentriq in combination with Avastin to show an improvement in liver cancer patients

Nov 22,2019: Roche presents positive results from the Phase III IMbrave150 study evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment  of loiver cancer.

As compared with sorafenib results shows that Tecentriq in combination with Avastin reduced the risk of death (OS) by 42% hazard ratio and reduced the risk of disease worsening or death (PFS) by 41%.

- Advertisement -

Every year, more that 750,000 individuals worldwide are diagnosed with HCC, the most common form of liver cancer and this is increasing day by day.                                                                                   https://www.roche.com/media/releases/med-cor-2019-11-22b.htm

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular